Corrigendum to “Neurocognitive dysfunction and predictors in non-CNS cancer patients: Rationale and methods for the neuro-oncology research at a South African academic hospital” [Heliyon 10(1) (January 2024) e23007] (Heliyon (2024) 10(1), (S2405844023102155), (10.1016/j.heliyon.2023.e23007))

In the original published version of this article, in paragraph 5 of 1. Background the authors wrote: Therefore, objective, and subjective assessments, as well as psychological assessments will be administered shortly after the diagnosis but before, during and following chemotherapy for the test group. The assessments will also be administered to the control group parallel to the test group. This should now state: Therefore, objective, and subjective assessments, as well as psychological assessments will be administered shortly after the diagnosis but before, after and following chemotherapy for the test group. The assessments will also be administered to the control group parallel to the test group. In the original published version of this article, numbering was not added to the subheading Objectives nor the objectives of 2. Materials and methods. This should now state: 2.1.2. Objective(s) 2.1.2.1 To determine the extent of OCF and SCF in non-CNS cancer patients undergoing chemotherapy over time (before, after and following chemotherapy treatment). 2.1.2.2 To determine the impact of chemotherapy associated cognitive changes (OCF and SCF) on the quality of life of non-CNS cancer patients. 2.1.2.3 To determine the relationship between chemotherapy associated cognitive functioning (OCF and SCF) and psychological functioning in non-CNS cancer patients. In the original published version of this article, in 2.2.1 Quantitative Arm, 2.2.2 Qualitative Arm, 2.5 Data Collection and 2.5.2.2.1. Quantitative arm of 2. Materials and methods, the authors wrote: 2.2.1. Quantitative arm The study is a quasi-experimental time series design. The study will collect data on the objective and subjective functioning, as well as the level of psychological distress of two groups of participants (non-CNS cancer group-Test group and Benign condition group-Control group). The test group will be assessed at comparable time points being before commencing chemotherapy (T0), at 3 months (during chemotherapy) (T1), at 6 months (completion of chemotherapy) (T2), and 12 months after chemotherapy treatment (T3). The same assessment timeline will also be adopted for the control group. 2.2.2. Qualitative arm The study will conduct face to face individual interviews and focus groups to gather the lived experiences of the patients. Individual interviews will be conducted at T0, T1, T2 and T3 while Focus groups will be conducted only at T3. 2.5. Data collection The study will utilize a blended approach of data collection using an electronically administered assessment battery consisting of sociodemographic variables, a neuropsychological battery consisting of objective and subjective neuropsychological tests and self-report psychological distress measures. Additionally, the study will also utilize a semi-structured interview guide informed by the Interpretive Phenomenological Analysis (IPA) to explore the participants ‘lived experience. Data will be collected at T0, T1, T2 and T3 for all the tests and interviews except for group interviews which will be conducted at T3 only. 2.5.2.2.1. Quantitative arm An assessment battery consisting of computerized objective neuropsychological tests, subjective neuropsychological tests, and self-report measures, will be administered to the test group before (T0) receiving chemotherapy, during treatment (T1), after completing the treatment cycle (T2) and 12 months following treatment (T3) in tandem with a control group. For participants that are not conversant with computer tests, paper-based tests will be administered. The administration time is estimated to be 1.3 h–2 h depending on the participant's response speed. This should now state: 2.2.1 Quantitative Arm The study is a quasi-experimental time series design. The study will collect data on the objective and subjective functioning, as well as the level of psychological distress of two groups of participants (non-CNS cancer group-Test group and Benign condition group-Control group). The test group will be assessed at comparable time points being before commencing chemotherapy (T0), after completing chemotherapy (T1), and 12 months after chemotherapy treatment (T2). The same assessment timeline will also be adopted for the control group. 2.2.2 Qualitative Arm The study will conduct face to face individual interviews and focus groups to gather the lived experiences of the patients. Individual interviews will be conducted at T0, T1 and T2 while Focus groups will be conducted only at T2. 2.5 Data Collection Additionally, the study will also utilize a semi-structured interview guide informed by the Interpretive Phenomenological Analysis (IPA) to explore the participants ‘lived experience’. Data will be collected at T0, T1, and T2 for all the tests and interviews except for group interviews which will be conducted at T2 only. 2.5.2.2.1. Quantitative arm An assessment battery consisting of computerized objective neuropsychological tests, subjective neuropsychological tests, and self-report measures, will be administered to the test group before (T0) receiving chemotherapy, after completing the treatment cycle (T1) and 12 months following treatment (T2) in tandem with a control group. For participants that are not conversant with computer tests, paper-based tests will be administered. The administration time is estimated to be 1.3 h–2 h depending on the participant's response speed. In the original published version of this article, in Figure 1 the bottom quadrilateral said ‘QAUL↔ QUANT’. This has now been updated to ‘QUAL ↔ QUANT’. The correct version of Figure 1 can be found below.[Formula presented] Diagram representing the study design: Convergent parallel mixed method design. The authors apologize for the errors. Both the HTML and PDF versions of the article have been updated to correct the errors.